Daiwa has issued a research report stating that SINOPHARM (01099) revenues have begun to stabilize, but a clear timeline for a rebound has yet to emerge. The company's 2026 guidance for retail pharmacy revenue projects year-on-year double-digit growth. The rating has been lowered from "Outperform" to "Hold," and the target price has been reduced from HK$21 to HK$18. Earnings per share for 2026 to 2028 are forecast to grow by 4.5%, 5.6%, and 8.5% year-on-year, respectively, which is 3% to 6% below market expectations.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments